Birchview Capital’s Bristol-Myers Squibb Rights CELG.RT Stock Holding History

Birchview Capital’s Portfolio CELG.RT Stock Details CELG.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.3K	Buy	+98,527	New	+$10.9K	0.01%	79

Other funds holding CELG.RT

Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Purkiss Capital Advisors Ridgefield, Connecticut $268M AUM 23.98% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $192B AUM 13.66% 1-Year Est. Return

Rothschild Investment LLC Chicago, Illinois $2.69B AUM 27.79% 1-Year Est. Return

Oakworth Capital Birmingham, Alabama $2.12B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Birchview Capital's CELG.RT Position: Q3 2026 in Review

Birchview Capital opened a new position in Bristol-Myers Squibb Rights (CELG.RT) in Q3 2026: 98,527 shares worth $12.3K. The stake represents 0.01% of the portfolio and ranks #79 among its holdings.

12 funds tracked by Wall St. Rank hold CELG.RT as of Q3 2026.

Birchview Capital held 98,527 shares of Bristol-Myers Squibb Rights worth $12.3K as of Q3 2026.
Bristol-Myers Squibb Rights was a new Birchview Capital position in Q3 2026.
Bristol-Myers Squibb Rights made up 0.01% of Birchview Capital's portfolio in Q3 2026, its #79 holding.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Rights as of Q3 2026.

Based on Birchview Capital's 13F filing for Q3 2026, filed 13 Nov 2026.